Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
about
Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidasesCurrent and future antiviral therapy of severe seasonal and avian influenzaHedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapyNew small-molecule drug design strategies for fighting resistant influenza AA review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges aheadInfluenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern VietnamWhat is the optimal therapy for patients with H5N1 influenza?Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A virusesProgress of small molecular inhibitors in the development of anti-influenza virus agents.Continuing challenges in influenza.MegaRibavirin aerosol for the treatment of influenza A virus infections in micePathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus sheddingSusceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.Avian influenza: the tip of the iceberg.Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.Oseltamivir in human avian influenza infection.Drugs in development for influenza.ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.Combination chemotherapy for influenza.Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.Newer influenza antivirals, biotherapeutics and combinations.Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.A near-fatal infection with oseltamivir-resistant seasonal influenza A in a previously healthy child: Case report.Designing anti-influenza aptamers: novel quantitative structure activity relationship approach gives insights into aptamer-virus interactionIntramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in miceCombinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.Animal Models for Influenza Virus Pathogenesis and Transmission.How to approach and treat viral infections in ICU patientsAdamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations.Mast cell-induced lung injury in mice infected with H5N1 influenza virus.Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective studyCombinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in MiceOseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in miceNovel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in miceCombination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokineticsComparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.
P2860
Q21142689-5794192E-CCFB-48B9-A226-B8D657D74C5AQ24656164-575F5AFE-1F4B-4519-80F0-0FA6209FC346Q27307203-4B7C81DA-E5D7-40C4-8415-DC748FA8851DQ28080554-09C88093-A1C7-48BE-A5EC-642AB4A5AB1BQ28382972-BEBEFB9B-9AAE-44D9-9867-237D0CE2DEFAQ28473743-3CCCBF26-6D23-47FC-82BC-985F7948C5CDQ28475630-0C981FD9-9A1F-43DD-96F6-395E4E39427BQ28479036-799B2EEA-7B00-488E-A6E4-9B3F187F3D0DQ30234943-DCE28DA5-CA78-46C6-8C71-8EF8C1D50CDCQ30363190-30BBC00A-368B-41C0-A8A7-BA544FCAB6E5Q30367819-DDD750DD-F5CF-42A4-B3DF-CCEDA818C830Q30374356-A3AF62F0-6D98-4737-AE51-F874FF04B75CQ30376004-3FC377B0-8E86-48D9-85A2-5EE8B3750DA7Q30378478-39338436-F943-4450-8E6B-84D02D1D904EQ30379095-E858B9FA-C82D-4E84-BFA4-E4200C1DBC8FQ30386487-AEADFD1C-2B1D-4612-918D-BFFE65395A1FQ30391218-F082697E-C40E-4B49-B858-2344314721C6Q30404586-DB77143A-E4EB-4688-A6E9-E578EE0C6930Q30407719-82BF56D6-A18C-47A0-83F6-C86C51BA0F02Q30408112-06347F23-1652-439C-AD42-9E9DD4CCA34FQ30427798-1A4FAD6F-7BB1-4856-8E14-155611B3EB31Q30456363-983881D4-5F25-4756-A64E-C861155DA8CAQ33559151-A4100A9F-CA8F-4689-8E57-2EE2CB79C005Q33593712-AA36B91F-3EF3-4EFC-931A-5EE8BADC6C89Q33638356-A4B1308B-7F36-4A50-80E0-4DCBCF107A81Q33761451-5DC84CDB-2AD2-4916-9E40-E54251F1DD88Q34159076-C885F920-E686-4255-8283-0F416DFBFFDAQ34714853-C095E5CB-1A4C-4581-BC92-39ACA0437D9CQ34894660-3DE90CBF-500C-4672-85A5-11D0219BECA5Q35175284-AECB52D3-9190-4BC9-B741-C7FF71BE5636Q35826260-7D13B6D7-DC30-4CBA-A6B2-3A472F205461Q36301052-3BC2D3C9-5E4D-4CCE-8ED9-D089A5337D83Q36566014-D1B204EC-6792-4379-BC5D-135FF19C8DBDQ36934209-34BEFA2C-7F00-44CF-8345-9DCF2BDF5837Q36949482-7955BC17-C648-4754-A740-C9492FAB08DBQ37001633-4ABF152F-E269-45DB-97C5-FE043DDE2586Q37190793-3C2AED8F-43F5-47D1-B094-0B10004095CBQ37549382-28B9D38D-29DB-4F25-AFDA-2E396DD70686Q38694084-FD3CB18D-ABC8-44C5-912D-D3E907E18DCDQ40622883-4CEFF6B9-BC9B-400E-85AC-C6904C891C78
P2860
Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
@ast
Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
@en
type
label
Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
@ast
Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
@en
prefLabel
Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
@ast
Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
@en
P2093
P1433
P1476
Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
@en
P2093
Erich Hoffmann
Natalia A Ilyushina
Rachelle Salomon
P304
P577
2007-01-01T00:00:00Z